Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective is to evaluate the ocular and non-ocular adverse events during the 6-months study period in patients treated with Lucentis (0.5 mg) vs. treated with Ozurdex
Inclusion criteria
- visual impairment due to macular edema following retinal vein occlusion (branch or central)